2:20 PM
 | 
Jan 13, 2017
 |  BioCentury  |  Finance

Advancing apoptosis

Ascentage to push forward with apoptosis candidates with $72M B round

A RMB500 million ($72 million) series B round will enable Ascentage Pharma Group Corp. Ltd. to generate clinical proof-of-concept data for two to three cancer candidates in three years.

Future Industry Investment Fund led the round, which closed on Dec. 27. New investors Shiyu Capital, Hidragon Capital and Founder KIP Capital and existing investors YuanMing Capital, Oriza Venture Fund and EFung Capital also participated.

Ascentage’s most advanced program is AT-101, a pan inhibitor of the B cell lymphoma 2 (BCL-2;

Read the full 413 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >